{"entity":{"id":"inge-van-der-sluis","kind":"person","name":"Inge M. van der Sluis","aka":[],"tldr":"Dutch paediatric oncologist who led the study showing that adding one course of blinatumomab to chemotherapy sharply improves survival for babies with KMT2A-rearranged leukaemia.","summary":"Inge van der Sluis is a paediatric oncologist at the Princess Máxima Center in Utrecht. She was first author of the 2023 New England Journal of Medicine report of the Interfant pilot study in which a single 28-day course of the bispecific antibody blinatumomab added to Interfant-06 chemotherapy gave two-year disease-free survival of over 80 percent in infants with KMT2A-rearranged acute lymphoblastic leukaemia, far higher than historical controls. She also studies asparaginase pharmacology.","asOf":"2026-09-18","links":[],"tags":["paediatric","leukaemia","immunotherapy","trialist"],"related":[],"cancers":["all-infant","all-leukemia","childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["princess-maxima"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-blinatumomab-infant-all-van-der-sluis-nejm-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Paediatric oncologist, Princess Máxima Center for Pediatric Oncology","institutionId":"princess-maxima","specialisms":["Infant leukaemia","Immunotherapy in paediatric leukaemia","Asparaginase"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sluis%5BAuthor%5D"}],"papers":[],"orcid":"0000-0002-5822-7668"},"route":"/people/inge-van-der-sluis/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"},{"id":"all-infant","kind":"cancer","name":"Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)","route":"/cancers/all-infant/"}],"institution":[{"id":"princess-maxima","kind":"institution","name":"Princess Máxima Center for Pediatric Oncology","route":"/institutions/princess-maxima/"}],"paper":[{"id":"paper-blinatumomab-infant-all-van-der-sluis-nejm-2023","kind":"paper","name":"Blinatumomab added to chemotherapy in infant KMT2A-rearranged acute lymphoblastic leukaemia","route":"/key-papers/paper-blinatumomab-infant-all-van-der-sluis-nejm-2023/"}]}}